These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Advanced drug delivery systems that target the vascular endothelium. Ding BS; Dziubla T; Shuvaev VV; Muro S; Muzykantov VR Mol Interv; 2006 Apr; 6(2):98-112. PubMed ID: 16565472 [TBL] [Abstract][Full Text] [Related]
4. Endothelial endocytic pathways: gates for vascular drug delivery. Muro S; Koval M; Muzykantov V Curr Vasc Pharmacol; 2004 Jul; 2(3):281-99. PubMed ID: 15320826 [TBL] [Abstract][Full Text] [Related]
5. Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules. Muro S; Muzykantov VR Curr Pharm Des; 2005; 11(18):2383-401. PubMed ID: 16022673 [TBL] [Abstract][Full Text] [Related]
6. Targeting vascular inflammation through emerging methods and drug carriers. Nong J; Glassman PM; Muzykantov VR Adv Drug Deliv Rev; 2022 May; 184():114180. PubMed ID: 35271986 [TBL] [Abstract][Full Text] [Related]
7. Targeting therapeutics to endothelium: are we there yet? Kiseleva RY; Glassman PM; Greineder CF; Hood ED; Shuvaev VV; Muzykantov VR Drug Deliv Transl Res; 2018 Aug; 8(4):883-902. PubMed ID: 29282646 [TBL] [Abstract][Full Text] [Related]
8. Biomedical aspects of targeted delivery of drugs to pulmonary endothelium. Muzykantov VR Expert Opin Drug Deliv; 2005 Sep; 2(5):909-26. PubMed ID: 16296786 [TBL] [Abstract][Full Text] [Related]
9. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
10. Targeted endothelial nanomedicine for common acute pathological conditions. Shuvaev VV; Brenner JS; Muzykantov VR J Control Release; 2015 Dec; 219():576-595. PubMed ID: 26435455 [TBL] [Abstract][Full Text] [Related]
11. In vitro characterization of leukocyte mimetic for targeting therapeutics to the endothelium using two receptors. Omolola Eniola A; Hammer DA Biomaterials; 2005 Dec; 26(34):7136-44. PubMed ID: 15953632 [TBL] [Abstract][Full Text] [Related]
12. Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. Howard M; Zern BJ; Anselmo AC; Shuvaev VV; Mitragotri S; Muzykantov V ACS Nano; 2014 May; 8(5):4100-32. PubMed ID: 24787360 [TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kim YG; Suga SI; Kang DH; Jefferson JA; Mazzali M; Gordon KL; Matsui K; Breiteneder-Geleff S; Shankland SJ; Hughes J; Kerjaschki D; Schreiner GF; Johnson RJ Kidney Int; 2000 Dec; 58(6):2390-9. PubMed ID: 11115072 [TBL] [Abstract][Full Text] [Related]
20. Role of integrated cancer nanomedicine in overcoming drug resistance. Iyer AK; Singh A; Ganta S; Amiji MM Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]